A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Glecirasib

This is a multicenter, open-label phase 2 study that will enroll KRASG12C mutated patients with locally advanced or metastatic NSCLC, receiving treatment (ABSK043 in combination with Glecirasib) in a 21-day combination cycle.

Trial Details

NCT ID
NCT07164170
Phase
PHASE2
Sponsor
Abbisko Therapeutics Co, Ltd
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • ABSK043 in combination with Glecirasib
Locations (sample)
  • Hefei, Anhui, China|31.86389,117.28083
  • Beijing, Beijing Municipality, China|39.9075,116.39723
  • Beijing, Beijing Municipality, China|39.9075,116.39723
  • Fuzhou, Fujian, China|26.06139,119.30611
  • Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

  • Prior to any protocol- specific procedures are performed, the patient should understand and voluntarily sign and date the written informed consent …
  • Gender was not limited patients aged ≥18 years at the time of signing the informed consent.
  • Histologically or cytologically confirmed locally advanced, unresectable, or metastatic non-small cell lung cancer (NSCLC).
  • For patients in the dose-escalation cohort (Part A) of the escalation part:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →